
At our annual meeting @CompoundVC , each investment team member presents a specific thesis. @shelbynewsad gave one on China vs. US in biotech. A select few slides from the presentation:
Both Hengrui and Isomorphic now have ~$50B valuations. One is China's largest innovative biopharma player, one is bio AI's largest... Which one will have more impact on human disease over the next 10 years? Which one will drive the biggest R&D Productivity improvements? Hengrui has 34 branded approved drugs, 100+ drugs in its clinical pipeline and 400+ ongoing clinical trials - and $4B in revenues. Isomorphic has its Drug Design Engine, that goes way beyond AlphaFold as a first-principles AI drug R&D architecture, and It has yet to put it's lead program into clinical testing, but is expected to in 2027 with many more after that... Both have lots of global partners. Both have tons of cash to invest. Both have enormous ambitions. Which one will deliver the most for patients and the ecosystem by 2036? China vs AI. Predator vs Alien. Godzilla vs Kong. The great "battle" of our time...



























